77,402 Shares in Revolution Medicines, Inc. $RVMD Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio purchased a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 77,402 shares of the company’s stock, valued at approximately $14,496,000.

A number of other large investors also recently bought and sold shares of the stock. State of Wyoming acquired a new stake in Revolution Medicines during the second quarter valued at $1,769,000. Handelsbanken Fonder AB increased its holdings in Revolution Medicines by 243.6% in the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock valued at $39,755,000 after buying an additional 150,500 shares in the last quarter. Eagle Health Investments LP acquired a new position in shares of Revolution Medicines in the fourth quarter worth about $9,231,000. Bank of New York Mellon Corp acquired a new position in shares of Revolution Medicines in the second quarter worth about $112,566,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Revolution Medicines during the 2nd quarter worth about $37,547,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial opportunity. Rasonque became the first broad RAS-targeted therapy approved for metastatic pancreatic cancer and Revolution Medicines’ first marketed product. The approval arrived roughly five weeks after filing through the FDA’s national priority voucher program. In the pivotal RASolute 302 trial, the treatment reportedly nearly doubled survival outcomes, supporting expectations for rapid adoption. RVMD Secures FDA Win
• Positive Sentiment: Analysts raised their valuations. Guggenheim increased its price target to $275 from $240 with a Buy rating, while HC Wainwright maintained a Buy rating and a $280 target. Analysts cited potential peak sales of approximately $11.5 billion, and RBC viewed the planned launch as comparatively rapid. Revolution Medicines FDA Approval and Peak Sales
• Neutral Sentiment: Much of the good news may already be reflected in the stock. RVMD recently reached an all-time high above $224 and its market capitalization approached $47 billion. Commentary suggests investors had already priced in a successful approval, limiting additional upside from the announcement. Revolution Medicines Valuation Analysis
• Negative Sentiment: Profit-taking and risk concerns are weighing on shares. Despite the “transformative” approval, the stock is facing a weekly decline as investors lock in gains after a more-than-fivefold rally. Revolution Medicines remains unprofitable, with analysts forecasting negative EPS for 2027, although losses are expected to narrow to $6.86 per share for the full year. Revolution Medicines Shares Despite FDA Approval

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $207.88 on Monday. The company’s 50-day simple moving average is $193.33 and its 200-day simple moving average is $148.95. Revolution Medicines, Inc. has a 52-week low of $37.56 and a 52-week high of $224.31. The firm has a market cap of $44.56 billion, a price-to-earnings ratio of -23.57 and a beta of 1.39. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period last year, the firm earned ($1.31) EPS. Equities analysts predict that Revolution Medicines, Inc. will post -8.85 EPS for the current fiscal year.

Analysts Set New Price Targets

RVMD has been the topic of a number of analyst reports. Needham & Company LLC raised their target price on Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. UBS Group upped their price target on Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a report on Friday. Mizuho increased their price target on Revolution Medicines from $185.00 to $215.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. HC Wainwright raised their price objective on Revolution Medicines from $195.00 to $280.00 and gave the company a “buy” rating in a report on Thursday. Finally, Oppenheimer boosted their price objective on Revolution Medicines from $230.00 to $260.00 and gave the company an “outperform” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $198.89.

Insider Buying and Selling

In other Revolution Medicines news, insider Mark A. Goldsmith sold 80,000 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the transaction, the insider owned 267,330 shares of the company’s stock, valued at $55,925,436. This represents a 23.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sushil Patel sold 5,580 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total value of $1,048,984.20. Following the completion of the transaction, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. This trade represents a 20.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 212,497 shares of company stock worth $38,206,486 in the last quarter. 7.60% of the stock is owned by insiders.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.